Thyroid cancer is the most common endocrine malignancy and has one of the best prognoses of all cancers: the five-year survival rate for differentiated thyroid cancer (papillary and follicular) exceeds 95%. Most patients are cured with thyroidectomy and, where indicated, radioactive iodine (RAI). The medical aid complexity is significant, however: thyroidectomy is a PMB-covered surgery; RAI treatment requires a specialist nuclear medicine facility; and post-surgical hypothyroidism — a lifelong consequence of thyroidectomy — is a CDL condition requiring ongoing levothyroxine supplementation.
What Is Thyroid Cancer?
Thyroid cancer arises from the cells of the thyroid gland. There are several types:
- Papillary thyroid carcinoma (PTC, ~80–85%): Slowest growing; best prognosis. Most common form. Spreads to cervical lymph nodes but rarely fatal.
- Follicular thyroid carcinoma (FTC, ~10–15%): Spreads via the bloodstream to lungs and bone. Stage-dependent prognosis.
- Medullary thyroid carcinoma (MTC, ~3–5%): Arises from C-cells (parafollicular cells); secretes calcitonin. Can be sporadic or associated with MEN2 syndrome.
- Anaplastic thyroid carcinoma (<1%): Most aggressive; rapidly lethal; rare.
Presentation: Usually discovered incidentally on ultrasound or as a painless thyroid nodule. Fine-needle aspiration cytology (FNAC) of a nodule is the key diagnostic step.
Is Thyroid Cancer a PMB Condition?
Yes. Thyroid cancer is a PMB Diagnosis and Treatment Pair (cancer DTP).
Your scheme must fund: - Diagnostic workup (ultrasound, FNAC, thyroid function tests) - Thyroidectomy (total or partial) - Radioactive iodine (RAI) therapy where indicated - Post-surgical monitoring (thyroglobulin, thyroid ultrasound) - Levothyroxine suppression therapy post-surgery
Post-surgical hypothyroidism (resulting from thyroidectomy) is also a CDL condition — hypothyroidism is on the CDL. This means lifelong levothyroxine must be funded as a minimum benefit under your chronic medication benefit.
How Does Medical Aid Cover Thyroid Cancer?
| Service | PMB/CDL? | Typical cover | Notes |
|---|---|---|---|
| Thyroid ultrasound | Yes — PMB (diagnostic) | Radiology benefit | TIRADS classification |
| FNAC (fine-needle aspiration) | Yes — PMB | Radiology/procedure benefit | Bethesda system cytology |
| Thyroid function tests (TSH, free T4) | Yes — PMB/CDL | Pathology benefit | |
| Thyroglobulin + anti-Tg antibodies | Yes — PMB | Pathology benefit | Post-operative tumour marker |
| Calcitonin (medullary cancer screening/monitoring) | Yes — PMB | Pathology benefit | |
| Thyroidectomy (total or partial) | Yes — PMB (cancer DTP) | Hospital benefit | Major operation; general surgeon or ENT |
| Neck dissection (lymph node clearance) | Yes — PMB (cancer DTP) | Hospital benefit | For nodal disease |
| Radioactive iodine (RAI / I-131) | Yes — PMB (cancer DTP) | Hospital benefit — nuclear medicine | Requires 3–5 day admission at nuclear medicine ward |
| Post-RAI whole-body scan | Yes — PMB (cancer DTP) | Nuclear medicine benefit | To confirm residual disease clearance |
| Levothyroxine (T4 replacement + TSH suppression) | Yes — CDL (hypothyroidism) | Chronic medication benefit | Lifelong; generic: R80–R200/month |
| Follow-up thyroid ultrasound (neck nodes) | Yes — PMB (cancer) monitoring | Radiology benefit | 6–12 monthly surveillance |
| Endocrinologist consultations | Yes — PMB (acute) | Specialist/day-to-day | Ongoing monitoring |
| Whole-body RAI scan (surveillance) | Yes — PMB (cancer) monitoring | Nuclear medicine benefit | Periodic; 1–5 years post-treatment |
| Sorafenib / lenvatinib (RAI-refractory thyroid cancer) | Yes — PMB (oncology) | Oncology benefit + exceptional needs | Very expensive; require exceptional-needs pre-auth |
| Vandetanib / cabozantinib (medullary thyroid cancer) | Yes — PMB (oncology) | Exceptional-needs authorisation | Targeted therapy for MTC; high cost |
Radioactive Iodine (RAI) — What to Expect
For differentiated thyroid cancer (papillary/follicular), RAI is given after total thyroidectomy to ablate any remaining thyroid tissue and treat possible microscopic residual or metastatic disease.
RAI process: 1. Post-thyroidectomy: Levothyroxine is withheld for 4–6 weeks (to allow TSH to rise, driving iodine uptake into residual thyroid cells), or recombinant TSH (rhTSH/Thyrogen) is injected — avoids the misery of hypothyroid withdrawal 2. Low-iodine diet for 1–2 weeks before RAI (no seafood, iodised salt, dairy from iodine-supplemented cows) 3. RAI administered as a capsule or liquid 4. 3–5 day isolation admission in a designated nuclear medicine ward (radiation isolation to protect others) 5. Post-RAI whole-body scan confirms ablation success
rhTSH (Thyrogen): Recombinant human TSH used instead of hypothyroid withdrawal before RAI. Significantly better quality of life. Covered under PMB for RAI preparation. Cost if pre-auth is needed: confirm with scheme.
Nuclear medicine facilities: Not all hospitals have nuclear medicine wards for RAI isolation. Confirm with your scheme which DSP nuclear medicine units are available in your area.
Post-Surgical Hypothyroidism — The CDL Pathway
Every patient who has a total thyroidectomy for thyroid cancer will be hypothyroid without medication. Levothyroxine is essential for life after total thyroidectomy.
After thyroid cancer, levothyroxine serves a dual purpose: 1. Hormone replacement (replacing the thyroid's function) 2. TSH suppression (keeping TSH low reduces stimulation of any residual thyroid cancer cells — especially important in the first 2–5 years after treatment)
CDL registration for hypothyroidism should be activated at the time of thyroidectomy. Do this before leaving the hospital if possible.
"I am having a total thyroidectomy for thyroid cancer. After surgery I will need lifelong levothyroxine. Please register my post-surgical hypothyroidism (ICD-10 E89.0) as a CDL condition and confirm levothyroxine is on my formulary."
Generic levothyroxine: R80–R200/month. Funded under the CDL hypothyroidism chronic medication benefit — lifelong, no benefit limit.
Day-to-Day Costs: What to Budget For
| Scenario | Estimated costs |
|---|---|
| Thyroidectomy + surgeon + anaesthesia (gap shortfall) | R15,000 – R50,000 (without gap cover) |
| RAI isolation admission (scheme-funded; gap cover for nuclear medicine specialist) | R5,000 – R20,000 gap shortfall |
| Annual monitoring (thyroglobulin, ultrasound, TSH) | R3,000 – R8,000/year |
| Levothyroxine lifelong | R80 – R200/month (CDL-funded) |
Gap cover is essential for the thyroidectomy — ENT or general surgeon specialising in thyroid surgery will charge above scheme tariff.
Key Questions to Ask Your Scheme
- Is my thyroid cancer registered as a PMB cancer DTP? Required for all oncology coverage.
- Which nuclear medicine units are DSP for RAI therapy? Not all hospitals have nuclear medicine wards.
- Has my post-thyroidectomy hypothyroidism been registered on the CDL? Levothyroxine must be CDL-funded.
- Is rhTSH (Thyrogen) covered for RAI preparation? Request written confirmation.
- Is gap cover notified before thyroidectomy? Essential.
Cross-Reference
Post-thyroidectomy hypothyroidism is managed identically to primary hypothyroidism — see the Hypothyroidism medical aid article for detailed CDL management guidance.
Talk to Eldon
Thyroid cancer has an excellent prognosis but requires correct sequencing: PMB cancer DTP activation, CDL hypothyroidism registration post-surgery, and gap cover for the thyroidectomy. AURA coordinates all three.
See which plans pay for thyroid cancer and post-surgical management →
CANSA helpline: 0800 22 6622